Clinical Trial Update: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) [Phase 2]

View source ↗

Summary

Clinical trial update on AbbVie RGX-314 gene therapy for diabetic retinopathy with or without center-involved diabetic macular edema; the Phase 2 study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• RGX-314 gene therapy

Snippet

Sponsor: AbbVie | Conditions: Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME) | Phase 2 | Status: ACTIVE_NOT_RECRUITING